1. Home
  2. AVDL vs UVE Comparison

AVDL vs UVE Comparison

Compare AVDL & UVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AVDL
  • UVE
  • Stock Information
  • Founded
  • AVDL 2015
  • UVE 1990
  • Country
  • AVDL Ireland
  • UVE United States
  • Employees
  • AVDL N/A
  • UVE N/A
  • Industry
  • AVDL Biotechnology: Pharmaceutical Preparations
  • UVE Property-Casualty Insurers
  • Sector
  • AVDL Health Care
  • UVE Finance
  • Exchange
  • AVDL Nasdaq
  • UVE Nasdaq
  • Market Cap
  • AVDL 784.6M
  • UVE 642.7M
  • IPO Year
  • AVDL 1996
  • UVE 1992
  • Fundamental
  • Price
  • AVDL $8.03
  • UVE $23.16
  • Analyst Decision
  • AVDL Strong Buy
  • UVE
  • Analyst Count
  • AVDL 7
  • UVE 0
  • Target Price
  • AVDL $18.86
  • UVE N/A
  • AVG Volume (30 Days)
  • AVDL 1.1M
  • UVE 192.0K
  • Earning Date
  • AVDL 05-07-2025
  • UVE 04-24-2025
  • Dividend Yield
  • AVDL N/A
  • UVE 2.75%
  • EPS Growth
  • AVDL N/A
  • UVE N/A
  • EPS
  • AVDL N/A
  • UVE 2.01
  • Revenue
  • AVDL $169,117,000.00
  • UVE $1,520,536,000.00
  • Revenue This Year
  • AVDL $50.53
  • UVE N/A
  • Revenue Next Year
  • AVDL $32.33
  • UVE $3.77
  • P/E Ratio
  • AVDL N/A
  • UVE $11.52
  • Revenue Growth
  • AVDL 504.79
  • UVE 9.27
  • 52 Week Low
  • AVDL $6.38
  • UVE $16.50
  • 52 Week High
  • AVDL $19.09
  • UVE $24.14
  • Technical
  • Relative Strength Index (RSI)
  • AVDL 54.47
  • UVE 58.59
  • Support Level
  • AVDL $6.38
  • UVE $21.19
  • Resistance Level
  • AVDL $8.22
  • UVE $22.95
  • Average True Range (ATR)
  • AVDL 0.48
  • UVE 0.85
  • MACD
  • AVDL 0.11
  • UVE -0.02
  • Stochastic Oscillator
  • AVDL 89.67
  • UVE 70.39

About AVDL Avadel Pharmaceuticals plc

Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.

About UVE UNIVERSAL INSURANCE HOLDINGS INC

Universal Insurance Holdings Inc is a private personal residential homeowner insurance company. The company develops, markets, and underwrites insurance products for consumers predominantly in the personal residential homeowners' lines of business and performs substantially all other insurance-related services for its primary insurance entities, including risk management, claims management, and distribution. The company generates revenue from the collection of premiums. It operates within Florida and across the United States. The company's primary insurance subsidiaries, (UPCIC) and (APPCIC) provide insurance for personal residential: homeowners, renters/tenants, condo unit owners, and other related coverages.

Share on Social Networks: